Open Access. Powered by Scholars. Published by Universities.®
Immunology and Infectious Disease Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Immunotherapy (6)
- Medical Specialties (3)
- Medicine and Health Sciences (3)
- Oncology (3)
- Biochemistry, Biophysics, and Structural Biology (2)
-
- Cell Biology (2)
- Cell and Developmental Biology (2)
- Laboratory and Basic Science Research (2)
- Anatomy (1)
- Animal Experimentation and Research (1)
- Biochemistry (1)
- Bioinformatics (1)
- Biological Phenomena, Cell Phenomena, and Immunity (1)
- Cancer Biology (1)
- Cellular and Molecular Physiology (1)
- Digestive System (1)
- Digestive System Diseases (1)
- Digestive, Oral, and Skin Physiology (1)
- Disease Modeling (1)
- Diseases (1)
- Gastroenterology (1)
- Genetics (1)
- Genetics and Genomics (1)
- Immunity (1)
- Medical Sciences (1)
- Molecular Biology (1)
- Physiology (1)
- Public Health (1)
- Institution
- Publication
- Publication Type
Articles 1 - 7 of 7
Full-Text Articles in Immunology and Infectious Disease
Screening Anti-Pd-L2 Peptides As Antitumor Ligands Using Phage Display, Chien Tran Phuoc
Screening Anti-Pd-L2 Peptides As Antitumor Ligands Using Phage Display, Chien Tran Phuoc
Honors Projects
Cancer still remains one of the top leading causes of death in America. Recently, programmed cell death protein 1 (PD-1) blockades have been demonstrated to be highly effective against various types of cancer. By blocking PD-1 from binding with their ligands (PD-L1 and PD-L2), the “off” signal to the immune system is inhibited, hence reinvigorating the immune cells to kill tumor cells. To date, despite PD-L1 and PD-L2 both interacting with PD-1, research efforts have only been focused on developing anti-PD-L1 inhibitors. Therefore, the work of this honor project has focused on finding anti-PD-L2 peptides by phage display, with the …
Understanding And Targeting The Immunosuppressive Tumor Microenvironment, Li Cai, Li Cai
Understanding And Targeting The Immunosuppressive Tumor Microenvironment, Li Cai, Li Cai
Dissertations & Theses (Open Access)
Immune checkpoint inhibitors (ICIs), such as anti-PD1/PD-L1 and anti-CTLA-4, have shown impressive antitumor efficacy by improving the activity of T cells. While these inhibitors work in many patients with various cancer types, they have minimal or no effect in many more patients. Mounting evidence indicates that, besides current known immune checkpoints, other immunosuppressive components in the tumor microenvironment (TME) need to be targeted to elicit the full immune responses.
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of immunosuppressive myeloid cells that are involved in cancer progression and therapeutic resistance. In this work, we demonstrated the essential role of MDSCs …
The Role Of The Hypoxia-Inducible Factor 2 In Pancreatic Cancer: Mechanisms Of Tumor Immunosuppression And Intestinal Radioprotection, Carolina Garcia Garcia
The Role Of The Hypoxia-Inducible Factor 2 In Pancreatic Cancer: Mechanisms Of Tumor Immunosuppression And Intestinal Radioprotection, Carolina Garcia Garcia
Dissertations & Theses (Open Access)
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with dismal prognosis. The only curative option for patients is surgery, but over 80% of patients are not surgical candidates. Unfortunately, PDAC is resistant to the three remaining options. PDAC is characterized by a profoundly hypoxic and immunosuppressive stroma, which contributes to its therapeutic recalcitrance. Alpha-smooth muscle actin+ (αSMA+) cancer-associated fibroblasts (CAFs) are the most abundant stromal component, as well as mediators of stromal deposition. The hypoxia-inducible factors (HIF1 and HIF2) coordinate responses to hypoxia, yet, despite their known association to poor patient outcomes, their functions within the PDAC tumor microenvironment (TME) …
The Herpes Simplex Virus Type-1 (Hsv-1), Vc2 Live-Attenuated Vaccine Strain Induces Robust Antitumor Immune Responses And Ameliorates Intra-Tumor Immunosuppression In An Immunocompetent B16f10-Derived Murine Melanoma Model, Ifeanyi Kingsley Uche
LSU Doctoral Dissertations
Current cancer immunotherapies include immune checkpoint inhibitors, adoptive cellular therapy, and cancer vaccines. While some of these therapies have met with great clinical success, they are associated with several limitations. Oncolytic virotherapy (OVT) has emerged as a bonafide promising immunotherapy, that uses viral infection to liberate tumor antigens in an immunogenic context to promote the development of anti-tumor immune responses. At present, Talimogene laherparepvec (T-VEC; Imlygic™), a modified type 1 herpes simplex virus (HSV-1) is the only FDA approved OVT for human cancer treatment (melanoma). While T-VEC is associated with limited response rates, its modest efficacy supports the continued development …
Determining The Role Of Dendritic Cells During Response To Treatment With Paclitaxel/Anti-Tim-3, Alycia Gardner
Determining The Role Of Dendritic Cells During Response To Treatment With Paclitaxel/Anti-Tim-3, Alycia Gardner
USF Tampa Graduate Theses and Dissertations
Intratumoral CD103+ dendritic cells (cDC1) are required for anti-tumor immune responses. In tumors that are poorly responsive to immunotherapeutic approaches targeting T cells, targeting cDC1 represents an alternative approach that may be useful in improving patient response rates. As such, it is critical to understand cDC1 function within tumors, and what may be preventing optimal function of cDC1. TIM-3 is a receptor that is highly expressed by cDC1 in murine and human mammary tumors, and TIM-3 blocking antibodies are currently being evaluated in clinical trials for a number of solid and hematological malignancies. In order to best design combinatorial therapeutic …
Profiling Durable Anti-Tumor Memory T Cell Responses In Long-Term Melanoma Survivors, Jichang Han
Profiling Durable Anti-Tumor Memory T Cell Responses In Long-Term Melanoma Survivors, Jichang Han
Dartmouth College Ph.D Dissertations
While T-cell responses to cancer immunotherapy have been avidly studied,
long-lived memory has been poorly characterized. Of melanoma patients who
receive immunotherapy, long-term survivors are frequently found to develop
melanoma-associated vitiligo. Our prior work showed in a preclinical model that
vitiligo skin sustained a long-lived CD8+ resident memory T cell (TRM) population,
playing key roles in perpetuating anti-tumor immunity. However, the characteristics
and longevity of these memory T cells in melanoma survivors have not been defined.
In the present studies, we probed both the CD8+ and CD4+ T cell responses,
focusing on memory T cell responses in a cohort of …
Determining Effective Treatment Regimens For Breast Cancer Using Combined Immunotherapy And Chemotherapy In Vivo, Akhila R. Kunuthuru, Laura Graham, Harry D. Bear Md, Phd
Determining Effective Treatment Regimens For Breast Cancer Using Combined Immunotherapy And Chemotherapy In Vivo, Akhila R. Kunuthuru, Laura Graham, Harry D. Bear Md, Phd
Undergraduate Research Posters
Breast cancer has the highest incidence rate of all cancers globally in women, and those of African descent, especially West African females, face higher rates of triple-negative breast cancer (TNBC), a more aggressive form of breast cancer. Immunotherapy for breast cancer is a relatively new treatment option, and research is ongoing to identify the best combination treatments for increasing survival of those diagnosed with TNBC. Eganelisib (IPI-549: a PI3K-gamma inhibitor that works to shift M2 macrophages to M1 to augment T cell function) with other combinatory treatments has shown promising results in reducing tumor growth and increasing survival in mice. …